Novel approaches to antifungal prophylaxis

Bibliography

• HUSAIN S, TOLLEMAR J, DOMINGUEZ EA et al.: Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation (2003) 75:2023–2029.
   PubMed Web of Science ®Google Scholar
• CLARK TA, HAJJEH RA: Recent trends in the epidemiology of invasive mycoses. Carr. Opin. Infect. Dis. (2002) 15:569-574. A comprehensive update on the epidemiology of fungal infections.
   Google Scholar
• HUSAIN S, ALEXANDER BD, MUNOZ P et al.: Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillusmycelial fungi. Clin. Infect. Dis. (2003) 37:221–229.
   PubMed Web of Science ®Google Scholar
• KULLBERG BJ, OUDE LASHOF AM:Epidemiology of opportunistic invasive mycoses. Eur. J. Med. Res. (2002) 7:183–191.
   PubMed Web of Science ®Google Scholar
• PATTERSON JE: Epidemiology of fungalinfections in solid organ transplant patients. Transpl. Infect. Dis. (1999) 1:229-236. Expert Op/n. lnvestig. Drugs (2004) 13(6)669
   Google Scholar
• REISS E, TANAKA K, BRUKER G etal.: Molecular diagnosis and epidemiology of fungal infections. Med. Mycol (1998) 36\(Suppl. 1):249–257.
   Google Scholar
• SAMARANAYAKE LP, FIDEL PL, NAGLIK JR et al.: Fungal infections associated with HIV infection. Oral Dis. (2002) 8\(Suppl. 2):151–160.
   Google Scholar
• SINGH N: The changing face of invasive aspergillosis in liver transplant recipients. Liver. Banspl. (2002) 8:1071–1072.
   PubMed Web of Science ®Google Scholar
• SINGH N: Fungal infections in the recipients of solid organ transplantation. Infect. Dis. Clin. North Am. (2003) 17:113-134, viii.
   Google Scholar
• WALSH TJ, GROLL AH: Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl. Infect. Dis. (1999) 1:247–261.
   PubMedGoogle Scholar
• WARNOCK DW, HAJJEH RA, LASKER BA: Epidemiology and prevention of invasive aspergillosis. Curr: Infect. Dis. Rep. (2001) 3:507–516.
   PubMedGoogle Scholar
• BLOT SI, HOSTE EA, VANDEWOUDE KH, COLARDYN FA: Estimates of attributable mortality of systemic candida infection in the ICU. .1. Crit. Care (2003) 18:130–131.
   PubMed Web of Science ®Google Scholar
• MILLER LG, HAJJEH RA, EDWARDS JE Jr: Estimating the cost of nosocomial candidemia in the united states. Clin. Infect. Dis. (2001) 32:1110.
   PubMed Web of Science ®Google Scholar
• RENTZ AM, HALPERN MT, BOWDEN R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. (1998) 27:781–788.
   PubMed Web of Science ®Google Scholar
• SINGH N, AVERY RK, MUNOZ P et al.: Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis. (2003) 36:46–52.
   PubMed Web of Science ®Google Scholar
• •An article that identifies patient subsets within the live transplant recipients who have increased risk of fungal infections, and thus would benefit more from prophylaxis.
   Google Scholar
• SLAVIN M, FASTENAU J, SUKAROM I et al.: Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Intj Infect. Dis. (2004) 8:111–120.
   PubMed Web of Science ®Google Scholar
• VAN GOOL R: The cost of treating systemic fungal infections. Drugs (2001) 61 (Suppl. 1):49–56.
   Google Scholar
• WENZEL RP: Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. (1995) 20:1531–1534.
   PubMed Web of Science ®Google Scholar
• •A classic paper on the risk factors, epidemiology and attributable mortality of candidemia.
   Google Scholar
• GUDLAUGSSON 0, GILLESPIE S, LEE K et al.: Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. (2003) 37:1172–1177.
   Google Scholar
• ••A recent update on the epidemiology andattributable mortality of candidemia.
   Google Scholar
• ALLAM ME DEL CASTILLO AS, DIAZ-MOLINA C, NAVAJAS RF: Invasive pulmonary aspergillosis: identification of risk factors. Scandj Infect. Dis. (2002) 34:819–822.
   PubMed Web of Science ®Google Scholar
• CHAPMAN RL: Candida infections in the neonate. Carr. Opin. Pediatr. (2003) 15:97–102.
   PubMed Web of Science ®Google Scholar
• EGGIMANN P, GARBINO J, PITTET D:Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. (2003) 3:685–702.
   PubMed Web of Science ®Google Scholar
• MAERTENS J, VREBOS M, BOOGAERTS M: Assessing risk factors for systemic fungal infections. Ear: Cancer Care (2001) 10:56–62.
   PubMed Web of Science ®Google Scholar
• PITTET D, MONOD M, SUTER PM, FRENK E, AUCKENTHALER R: Candida colonization and subsequent infections in critically ill surgical patients. Ann. &mg. (1994) 220:751–758.
   Web of Science ®Google Scholar
• •A classic paper describing the relationship between colonisation and invasive candidiasis.
   Google Scholar
• DUPONT H, BOURICHON A, PAUGAM-BURTZ C, MANTZ J, DESMONTS JM: Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit. Care Med. (2003) 31:752–757.
   Google Scholar
• •A new prediction rule for isolation of Candida in peritoneal fluid.
   Google Scholar
• GARBINO J, LEW DP, ROMAND JA et al.: Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. (2002) 28:1708–1717.
   PubMed Web of Science ®Google Scholar
• ••The most recent clinical trial of prophylaxis of Candida in the ICU setting with fluconazole.
   Google Scholar
• PAPHITOU NI, OSTROSKY-ZEICHNER L, REX JH: Developing criteria for risk-stratified prophylaxis (PRX) of invasive candidiasis (IC) in the ICU. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (2002) Abstract M–1239.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION; INFECTIOUS DISEASE SOCIETY OF AMERICA; AMERICAN SOCIETY OF BLOOD AND MARROW TRANSPLANTATION: Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm. Rep. (2000) 49:1–125.
   Google Scholar
• ••Societal guidelines supporting the use offluconazole prophylaxis in bone marrow transplant recipients.
   Google Scholar
• GOODMAN JL, WINSTON DJ, GREENFIELD RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl. I Med. (1992) 326:845–851.
   PubMed Web of Science ®Google Scholar
• •Landmark study that made the use of fluconazole prophylaxis in bone marrow transplant recipients a standard.
   Google Scholar
• MARR KA, SEIDEL K, SLAVIN MA et al: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood (2000) 96:2055–2061.
   PubMed Web of Science ®Google Scholar
• MARR KA: Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Oncology (2001) 15:15–19.
   PubMedGoogle Scholar
• ALEXANDER BD: Prophylaxis of invasive mycoses in solid organ transplantation. Carr: Opin. Infec. Dis. (2002) 15:583–589.
   PubMed Web of Science ®Google Scholar
• •Excellent review of fungal infections in solid organ transplantation.
   Google Scholar
• SINGH N: Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect. Dis. (2003) 3:156–161.
   PubMed Web of Science ®Google Scholar
• WINSTON DJ, BUSUTTIL RW: Randomized controlled trial of oral itraconazole solution versus intravenous/ oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation (2002) 74:688–695.
   PubMed Web of Science ®Google Scholar
• WINSTON DJ, PAKRASI A, BUSUTTIL RW: Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1999) 131:729–737.
   PubMed Web of Science ®Google Scholar
• •Landmark study in which fluconazole prophylaxis was introduced into liver transplantation.
   Google Scholar
• WINSTON DJ, HATHORN JW, SCHUSTER MG, SCHILLER GJ, TERRITO MC: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am. J. Med. (2000) 108:282–289.
   PubMed Web of Science ®Google Scholar
• WINSTON DJ, MAZIARZ RT, CHANDRASEKAR PH et al.: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Intern. Med. (2003) 138:705–713.
   PubMed Web of Science ®Google Scholar
• HADJILIADIS D, HOWELL DN, DAVIS RD et al.: Anastomotic infections in lung transplant recipients. Ann. Transplant (2000) 5:13–19.
   PubMedGoogle Scholar
• HAMACHER J, SPILIOPOULOS A, KURT AM, NICOD LP: Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur: Respir. J. (1999) 13:180–186.
   PubMed Web of Science ®Google Scholar
• PATTERSON TF: Approaches to fungal diagnosis in transplantation. Transpl. Infect. Dis. (1999) 1:262–272.
   PubMedGoogle Scholar
• DREW RH, DODDS ASHLEY E, BENJAMIN DK, JR. et al.: Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation (2004) 77:232–237.
   Google Scholar
• •Very recent clinical trial showing the safety of a lipid formulation of amphotericin B in the setting of lung transplantation.
   Google Scholar
• MONFORTE V, ROMAN A, GAVALDA J et al.: Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation (2003) 75:1571–1574.
   PubMed Web of Science ®Google Scholar
• BOW EJ, LAVERDIERE M, LUSSIER N et al.: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer (2002) 94:3230–3246.
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis of the use of antifungalprophylaxis in severe neutropenia.
   Google Scholar
• GLASMACHER A, PRENTICE A, GORSCHLUTER M et al.: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol (2003) 21:4615–4626.
   PubMed Web of Science ®Google Scholar
• EGGIMANN P, FRANCIOLI P, BILLE J et al.: Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Grit. Care Med. (1999) 2 7: 10 6 6–1 0 7 2.
   Google Scholar
• PELZ RK, HENDRIX CW, SWOBODA SM et al: Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Stow. (2001) 233:542–548.
   Google Scholar
• ••Landmark study on the use of fluconazoleprophylaxis for critical care.
   Google Scholar
• KAUFMAN D, BOYLE R, HAZEN KC et al.: Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl. J. Med. (2001) 345:1660–1666.
   PubMed Web of Science ®Google Scholar
• ••Landmark study on the use of fluconazoleprophylaxis for neonatal intensive care.
   Google Scholar
• MCGUIRE W, CLERIHEW L, AUSTIN N: Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst. Rev (2003) CD003850.
   Google Scholar
• HOOD S, DENNING DW: Treatment of fungal infection in AIDS. I. Antimicrob. Chemother. (1996) 37(Suppl. B):71–85.
   Google Scholar
• LORTHOLARY 0, DENNING DW, DUPONT B: Endemic mycoses: a treatment update. I Antimicrob. Chemothei: (1999) 43:321–331.
   Google Scholar
• MARTY F, MYLONAKIS E: Antifungaluse in HIV infection. Expert Opin. Pharmacother: (2002) 3:91–102.
   PubMedGoogle Scholar
• •Excellent review on the use of antifungals for HIV/AIDS.
   Google Scholar
• STEVENS DA: Management of systemic manifestations of fungal disease in patients with AIDS. Am. Acad. Dermatol (1994) 31:S64–67.
   PubMed Web of Science ®Google Scholar
• SHENG WH, HUNG CC, CHEN MY, HSIEH SM, CHANG SC: Successful discontinuation of fluconazole as secondary prophylaxis for cryptococcosis in AIDS patients responding to highly active antiretroviral therapy. Int. j STD AIDS (2002) 13:702–705.
   PubMed Web of Science ®Google Scholar
• ROLLOT F, BOSSI P, TUBIANA R et al:Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy. AIDS (2001) 15:1448–1449.
   PubMed Web of Science ®Google Scholar
• NELSON MR, FISHER M, CARTLEDGE J, ROGERS T, GAZZARD BG: The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS (1994) 8:651–654.
   PubMed Web of Science ®Google Scholar
• HOEPRICH PD: Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin. Infect. Dis. (1992) 14\(Suppl. 1):5114–119.
   Google Scholar
• •Classic article detailing the history and evolution of therapy with amphotericin B.
   Google Scholar
• FANOS V, CATALDI L: Amphotericin B-induced nephrotoxicity: a review. Chemother: (2000) 12:463–470.
   Web of Science ®Google Scholar
• HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. (1996) 22\(Suppl. 2):5133–144.
   Google Scholar
• HERBRECHT R, NATARAJAN-AME S, NIVOIX Y, LETS CHER-BRUV: The lipid formulations of amphotericin B. Expert Opin. Pharmacother. (2003) 4:1277–1287.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, REX JH: Lipid-based antifungal agents: current status. Curt Pharm. Des. (2001) 7:393–415.
   PubMed Web of Science ®Google Scholar
• •Excellent review on the lipid formulations of amphotericin B.
   Google Scholar
• MARR KA, CRIPPA F, LEISENRING W et al.: Itraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood (2003) 103:527–533
   Google Scholar
• MARTIN MV: The use of fluconazole and itraconazole in the treatment of candida albicans infections: a review. J. Antimicrob. Chemother: (2000) 45: 555.
   PubMed Web of Science ®Google Scholar
• KAUFMAN D: Strategies for prevention of neonatal invasive candidiasis. Semin. Perinatol (2003) 27:414–424.
   PubMed Web of Science ®Google Scholar
• EGGIMANN P, GARBINO J, PITTET D: Management of Candida species infections in critically ill patients. Lancet Infect. Dis. (2003) 3:772–785.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR: Itraconazole: managing mycotic complications in immunocompromised patients. Semin. Oncol (1998) 25:58–63.
   PubMed Web of Science ®Google Scholar
• GROLL AH, WALSH TJ: Antifungal chemotherapy: advances and perspectives. Swiss Med. Wkly (2002) 132:303–311.
   PubMed Web of Science ®Google Scholar
• KOKS CH, MEENHORST PL, BULT A, BEIJNEN JH: Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of
   Google Scholar
• Expert Opin. Investig. Drugs (2004) 13(6) fluconazole-resistant oral candidosis in HIV-infected persons. Pharmacol Res (2002)46:195–201. PANDYA NA, ATRA AA, RILEY U, PINKERTON CR: Role of itraconazole in haematology/oncology. Arch. Drs. Child. (2003) 88:258–260.
   Google Scholar
• KATZ HI: Drug interactions of the newer oral antifungal agents. Br. .1. Dermatol (1999) 141\(Suppl. 50:26–32.
   Google Scholar
• ••Excellent review on the drug interactionsof antifungal agents.
   Google Scholar
• GUPTA AK, TOMAS E: New antifungal agents. Dermatol Clin. (2003) 21:565–576.
   PubMed Web of Science ®Google Scholar
• GHANNOUM MA, KUHN DM: Voriconazole - better chances for patients with invasive mycoses. Eur: .1. Med. Res. (2002) 7:242–256.
   Google Scholar
• HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl. .1. Med. (2002) 347:408–415.
   Google Scholar
• ••Landmark study on the use of voriconazolefor the treatment of invasive aspergillosis.
   Google Scholar
• HOFFMAN HL, ERNST EJ, KLEPSER ME: Novel triazole antifungal agents. Expert Opin. Investig. Drugs (2000) 9:593–605.
   PubMed Web of Science ®Google Scholar
• HOFFMAN HL, RATHBUN RC: Review of the safety and efficacy of voriconazole. Expert Opin. Investig. Drugs (2002) 11:409–429.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, REX JH: Ravuconazole Eisai/ Bristol-Myers Squibb. Carr: Opin. Investig. Drugs (2002) 3:555–561.
   PubMedGoogle Scholar
• PATTERSON TF: Role of newer azoles in surgical patients. Chemothec (1999) 11:504–512.
   PubMed Web of Science ®Google Scholar
• STEINBACH WJ, PERFECT JR: Newer antifungal therapy for emerging fungal pathogens. Int. J. Infect. Drs. (2003) 7:5–20.
   PubMedGoogle Scholar
• •Excellent overview of new antifungal agents.
   Google Scholar
• DENNING DW: Echinocandin antifungal drugs. Lancet (2003) 362:1142–1151.
   PubMed Web of Science ®Google Scholar
• ••Authoritative and comprehensive reviewon the echinocandin drugs.
   Google Scholar
• KURTZ MB, DOUGLAS CM: Lipopeptide inhibitors of fungal glucan synthase. Med. Vet. Mycol (1997) 35:79-86. ao. WIEDERHOLD NP, LEWIS RE: The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs (2003) 12:1313–1333.
   Google Scholar
• CHANDRASEKAR PH, MANAVATHU EK: Caspofungin. Drugs Today (2002) 38:829–846.
   PubMed Web of Science ®Google Scholar
• VAN BURIK J-A, RATANATHARATHORN V, LIPTON J et al.: Randomized, double-blind trial of micafungin (MI) versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant, NIAID/BAMSG protocol 46. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (2002) Abstract M–1238.
   Google Scholar
• ••Landmark study in which an echinocandinwas first studied for a prophylaxis indication.
   Google Scholar
• LEATHER HL, WINGARD JR: Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom? Carr: Opin. Infect. Drs. (2002) 15:369–375.
   Web of Science ®Google Scholar
• ALEXANDER BD: Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl. Infect. Drs. (2002) 4\(Suppl. 3):32–37.
   Google Scholar
• ••Comprehensive review on the newdiagnostic techniques in medical mycology.
   Google Scholar
• REISS E, OBAYASHI T, ORLE K, YOSHIDA M, ZANCOPE-OLIVEIRA RM: Non-culture based diagnostic tests for mycotic infections. Med. Mycol. (2000) 38\(Suppl. 1):147–159.
   Google Scholar
• RICHARDSON MD, KOKKI MH: New perspectives in the diagnosis of systemic fungal infections. Ann. Med. (1999) 31:327–335.
   PubMed Web of Science ®Google Scholar
• KWAK EJ, HUSAIN S, OBMAN A et al: Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J. Clin. MicrobioL (2004) 42:435–438.
   PubMed Web of Science ®Google Scholar
• STEVENS DA: Diagnosis of fungal infections: current status. Antimicrob. Chemother: (2002) 49\(Suppl. 1):11–19.
   Google Scholar
• OBAYASHI T: [Plasma (1 glucan determination for screening deep mycosis]. Rinsho Byori (1996) 44:528–532.
   PubMedGoogle Scholar